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Abstract
Schizophrenia is a chronic and debilitating psychiatric condition affecting slightly more than 1% of the population
worldwide and it is a multifactorial disorder with a high degree of heritability (80%) based on family and twin studies.
Increasing lines of evidence suggest intermediate phenotypes/endophenotypes are more associated with causes of the
disease and are less genetically complex than the broader disease spectrum. Negative symptoms in schizophrenia are
attractive intermediate phenotypes based on their clinical and treatment response features. Therefore, our objective was to
identify genetic variants underlying the negative symptoms of schizophrenia by analyzing two genome-wide association
(GWA) data sets consisting of a total of 1,774 European-American patients and 2,726 controls. Logistic regression analysis of
negative symptoms as a binary trait (adjusted for age and sex) was performed using PLINK. For meta-analysis of two
datasets, the fixed-effect model in PLINK was applied. Through meta-analysis we identified 25 single nucleotide
polymorphisms (SNPs) associated with negative symptoms with p,561025. Especially we detected five SNPs in the first
two genes/loci strongly associated with negative symptoms of schizophrenia (Pmeta-analysis,6.22610
26), which included
three SNPs in the BCL9 gene: rs583583 showed the strongest association at a Pmeta-analysis of 6.00610
27 and two SNPs in the
C9orf5 (the top SNP is rs643410 with a p = 1.29 61026). Through meta-analysis, we identified several additional negative
symptoms associated genes (ST3GAL1, RNF144, CTNNA3 and ZNF385D). This is the first report of the common variants
influencing negative symptoms of schizophrenia. These results provide direct evidence of using of negative symptoms as an
intermediate phenotype to dissect the complex genetics of schizophrenia. However, additional studies are warranted to
examine the underlying mechanisms of these disease-associated SNPs in these genes.
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Introduction
Schizophrenia (SCZ) is one of the most tragic psychiatric
disorders with a high degree of genetic and clinical heterogeneity
and a prevalence of approximately 1% worldwide. Given its
debilitation, morbidity, mortality and economic burden, SCZ
represents a major public health concern and an important topic
in health research. Schizophrenia is known to be a multifactorial
disorder with a demonstrated heritability of 80% in family studies
and meta-analysis of multiple twin studies [1,2]. While the number
of genes potentially implicated in SCZ has been estimated to be
over 1000, the progress in the identification of susceptibility genes
has been slow. Previous functional studies have not been
successfully replicated, which may be due, at least in part, to the
inherent limitations associated with assessing phenotypic hetero-
geneity, using too broad phenotypes, or a lack of consideration of
the effect of the disease-associated single nucleotide polymor-
phisms (SNPs) on gene regulation. This highlights an urgent need
for re-thinking strategic, complementary approaches to identify
true biomarkers for the disorder. Molecular genetics technology
development and the results from the recent genome-wide
association (GWA) meta-analyses suggest a number of genes/loci
to be associated with the broader SCZ spectrum of phenotypes;
however, with regard to the identified causative variants, it is likely
that genetic variants with a more definitive effect on SCZ
phenotypes are still missing.
It has been well documented that using intermediate pheno-
types may aid in the genetic dissection of neuropsychiatric diseases
like SCZ (see review in [3]). Intermediate phenotypes, in contrast
to broad phenotypes, appear to follow simple inheritance patterns
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allowing for genetic linkage and association study of patients [4].
Therefore, using an intermediate phenotype approach permits
mapping of the effect of individual risk genes based on
neurobiological parameters, known to be associated with causes
of SCZ rather than targeting the effects of the disorder, which are
believed to be less genetically complex than those associated with
the disorder itself [4]. A recent study with a focus on a number of
SCZ-related intermediate phenotypes (e.g., neurophysiological
and neurocognitive data), examined 1536 SNPs and identified a
number of genetic variants that were associated with 12 SCZ
intermediate phenotypes. This finding supports the use of relevant
intermediate phenotypes and the bootstrap total significance test
for identifying genetic variation underlying the etiology of SCZ
[5], and provides evidence that using SCZ-related intermediate
phenotypes will increase the chance of detecting genetic linkage
and association not feasible with the broader spectrum of SCZ
[3,4]. Among the SCZ intermediate phenotypes, negative
symptoms of SCZ are of particular interest. One feature of the
negative symptoms of SCZ is its high degree of specificity and
sensitivity, which is responsible for major impairments in
functionality, and often has an onset before other diagnostic
criteria are present [6]. Moreover, negative symptoms are the most
potent predictor for a poor long-term outcome [7]. The
therapeutic response of negative symptoms to antipsychotic
treatment has been reported as being mild to almost absent [8].
Among patients with negative symptoms, each may present with a
different combination of symptoms and likewise, have a distinctive
evolution and response to treatment.
SCZ genetic association studies suggest an association between
negative symptoms of SCZ and the Cys311 allele in DRD2 gene,
and this may account for the observed differences in negative
symptoms presentation (see review in [9]). Furthermore, results of
a pharmacogenetics study suggested an association between the
variants of type-three metabotropic glutamate receptor gene
(GRM3) and negative symptoms of SCZ improvement when the
patients were treated with clozapine [10]. The authors concluded
that the GRM3 genetic variants may be useful predictors of
negative symptom improvement in persons treated with olanza-
pine as well. Another pharmacogenetic study also demonstrated
that patients with a Ser311Cys genotype of DRD2 gene showed
significant improvements with a larger change in scores for
negative symptoms of SCZ as compared to patients with a
Ser311Ser genotype over the course of 42 days of treatment with
risperidone [11]. Further, an animal study using the D2R-OE
mouse model [12] and the clinical observations in human subjects
[13,14] demonstrate that the severity of cognitive symptoms
correlated more highly with the negative symptoms than with the
positive symptoms of SCZ. Moreover, a recent study using a
genetic imaging approach demonstrated epistatic interactions
between the FGF mouse and the glypican 1 gene on brain
development. The authors concluded that this model may be
useful for investigating the negative symptoms of SCZ [15].
Based on the genetics, pharmacological and imaging studies
discussed above, we hypothesize that there is a genetic basis for the
presence of negative symptoms among patients with SCZ. The
conventional GWA study approach is a powerful tool to identify
disease-related genes for many common human disorders and
other phenotypes (Wellcome Trust Case Control Consortium
2007 [16]). Recently, GWA experiments identified several genes
associated with SCZ (such as ZNF804A, NRGN, RELN, TCF4, and
variants in the MHC) and yielded remarkable new experimental
evidence leading to a better understanding of the genetic models
and the biological risk factors involved in SCZ [2,17]. Until now,
no study has focused on GWA analysis of negative symptoms of
SCZ. In the present study we use two existing GWA-data sets
(729,454 markers) and large sample sizes (1774 cases with negative
symptoms of SCZ and 2726 controls) to identify novel variants
associated with negative symptom-susceptibility.
Results
Genotype Quality Control and Descriptive Statistics
We removed SNPs with HWE p,0.00001 or call rates ,95%
or minor allele frequency (MAF) ,1%. In total, 722,112 SNPs
were left for the GAIN sample and 711,137 SNPs were remained
for the nonGAIN sample. The details about these subjects were
described elsewhere [18–20]. After merging SNP genotype data
with phenotype data and removing outlier individuals based on
the principal-component analysis, 950 cases with negative
symptoms and 1,378 controls (1,298 males and 1,040 females)
were left in the GAIN sample while 824 cases and 1,348 controls
(1,258 males and 924 females) were left in the nonGAIN sample
(Table 1).
Genome-wide Association Analysis of Negative
Symptoms of SCZ
We identified 25 SNPs associated with negative symptoms at p
values ,561025 in the meta-analysis (Table 2). These 25 SNPs
were located with and/or near 18 different genes/loci. The best
disease-associated SNP rs583583 (p = 6.061027, Table 2) at
1q21.2 within B-cell CLL/lymphoma 9 (BCL9) gene. Interestingly,
two SNPs (rs583583 and rs828836) in this gene were found to be
located at biologically conserved regions among the different
species according to the UCSC Genome browser (http://genome.
ucsc.edu/, NCBI36/hg18). The second interesting locus was
rs643410 (p = 1.2961026, Table 2) at 9q31 within C9orf5. One
(rs838836) of three SNPs on this locus was located at a conserved
region. The C9orf5 gene has been shown to be associated with
prostate cancer [21]. The third disease-associated gene identified
was the ST3 beta-galactoside alpha-2,3-sialyltransferase 1
(ST3GAL1, also called SIAT4A) and it was also associated with
negative symptoms of SCZ (p = 1.7561025, Table 2).
However, only one SNP (rs10167072) in the RNF144 gene was
associated with negative symptoms of SCZ (p = 4.0661025,
Table 2). One previous study reported that a SNP (rs6741819)
in the RNF144 gene mediated the metabolic side effects of the
antipsychotic drug (risperidone) at genome wide significant level
(p = 2.4361027) in 738 patients with SCZ [22].
Table 1. Descriptive Characteristics of Negative Symptoms of
SCZ and Controls.
Negative Symptoms Controls
GAIN nonGAIN GAIN nonGAIN
Number 950 824 1378 1348
Sex, N (%)
Males 664 (69.9%) 588 (70.1%) 634 (46%) 670 (49.7%)
Females 296 (30.1%) 246 (29.9%) 744 (54%) 678 (50.3%)
Age, years
Mean 6 SD 43.8611.2 43.0611.7 51.1616.9 49.8615.8
Range 15–86 18–79 18–90 18–90
SCZ, schizophrenia.
doi:10.1371/journal.pone.0051674.t001
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One intronic SNP (rs16924239) at the CTNNA3 gene was
located at a conserved genomic region and was shown to be
significantly associated with negative symptoms of SCZ
(p = 1.6461025, Table 2).
The other two associated SNPs (rs2060531 and rs9869330) lie
within an interesting candidate gene and may warrant further
investigation: the negative symptoms-associated gene was
ZNF385D, which is located at 3p24. Two SNPs from this gene
showed significant associations with negative symptoms of SCZ
with p values of 3.7261025 and 4.0261025 respectively.
All p-values based on Q statistics were larger than 0.05 (except
for rs2945741 with p = 0.031), which indicated that there was no
heterogeneity for these SNPs between the GAIN and the
nonGAIN samples (Table 2). The Q-Q plot for meta-analyses is
presented in Figure 1. Table 2 also revealed that most SNPs were
associated with negative symptoms of SCZ in both the GAIN and
the nonGAIN samples (p,0.05). Applying a permutation proce-
dure for multiple test correction also yielded significant p values
(Table 2, corrected empirical p-values). Eighteen of the top 25
SNPs for the GAIN sample and 12 of the top 25 SNPs for the
nonGAIN sample had corrected p,0.05 after permutation tests
(Table 2).
Next, we thought it might be interesting to test disease-
associated variants between the SCZ with and without negative
symptoms, however, sample size is small for the SCZ without
negative symptoms (183 and 242 individuals for GAIN and
nonGAIN samples, respectively), clearly, it will limit power to
adequately test for association.
In silico Analysis
After observing that the negative symptoms-associated SNPs
were located in intron regions of the candidate genes/loci, we
evaluated whether these variants were located in regions of the
gene that might have potential functional importance. The
sequences containing the associated SNPs were examined for
microRNA binding sites, splicing sites, regulatory gene regions,
and species-conserved regions. We hypothesized that the negative
symptoms-associated common variants in species-conserved re-
gions may be more functionally important than common variants
in non-conserved regions. Using the UCSC Genome browser
(http://genome.ucsc.edu/, NCBI36/hg18), we found that fifteen
out of 25 disease-associated SNPs were located at species-
conserved regions (Table 2).
Furthermore, we performed gene ontology analysis to see
whether any gene ontology categories are overrepresented among
negative symptoms of SCZ associated-SNPs with low p values
[23]. Results of gene ontology analysis for negative symptoms of
SCZ associated SNPs with p Meta-analysis,3.04610
25, gene
ontology categories with enrichment p-values ,0.05 are shown
in Table 3.
Discussion
Given the animal study [15], clinical [7], pharmacological
[8,10,11], and imaging genetic and psychiatric genetic studies
[9,24], we hypothesized that genetic variants will be differentially
associated with negative symptoms of SCZ by examining the two
existing GWA -SCZ data sets. As far as we know, this is the first
report of a GWA study looking at negative symptoms in SCZ. We
have identified several new genes associated with negative
symptoms of SCZ. These major findings, for the first time,
provide pilot evidence that supports the use of negative symptoms
as an intermediate phenotype to dissect the complex genetics of
schizophrenia. It is possible that multiple genes may contribute to
the negative symptoms of SCZ susceptibility. However, additional
studies are warranted to examine the underlying mechanisms of
these disease-associated genes.
Although none of the SNPs reached the genome-wide
significance threshold (p,561028), many SNPs were very close
Figure 1. Quantile-quantile (Q-Q) plot of the observed versus expected –log 10 (p) values for the meta-analysis. Y-value: observed test
statistic and X-value: expected statistic under the global null hypothesis of no association.
doi:10.1371/journal.pone.0051674.g001
Association with Schizophrenia-Negative Symptoms
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e51674
to this level. Three SNPs, rs583583, rs2275552 and rs6674938, in
the BCL9 gene at chromosome 1q21.1 showed significant
associations to the negative symptoms of SCZ, with rs583583
being the strongest of all markers tested in the meta-analyses. It is
noteworthy that the BCL9 gene is expressed in all tissues and has
two transcripts: a major 6.3-kb transcript and a less prominent 4.2-
kb transcript [25]. One previous study reported that the BCL9
protein is required for efficient T-cell factor–mediated transcrip-
tion in the Wnt signaling pathway [26], which has been suggested
to be involved in the pathophysiology of mental disorders using
animal studies [27]. Furthermore, increasing lines of evidence
suggests that the Wnt signaling pathway influences neuroplasticity,
cell survival, and adult neurogenesis [27]. Recent human genetic
studies also reported that some BCL9 variants are associated with
SCZ in the Asian population [28], but not associated with bipolar
disorder (BD) in the Caucasian population [29]. Copy number
variant (CNV) analysis also revealed that large recurrent
microdeletions at 1q21.1 (where the BCL9 gene is located) were
associated with SCZ [30]. Soon after, results showing the
association of 1q21 in SCZ was replicated in 1,433 SCZ cases
and 33,250 matched healthy controls in the Phase I study and
3,285 cases and 7,951 controls in a Phase II study [24,31]. There is
a well-documented, peer-reviewed body of scientific publications
showing that CNVs in human chromosome 1q21, where the BCL9
gene is located were strongly associated with SCZ (for review
please see [32]) as well as rare CNVs (deletions and duplications)
observed in SCZ in a number of independent studies (for review,
please see [33]). It might be interesting to examine CNV on 1q21
among the patients with negative symptoms of SCZ in the future.
The second top signal came from the variants of C9orf5 gene
(also known as CG2; CG-2; TMEM245; FLJ23668; and
FLJ33224) at 9q31. A previous genome-wide scan demonstrated
linkage for an 11 cM region of human chromosome 9q31–33 for
familial dysautonomia which is a disorder of the autonomic
nervous system affecting the development and survival of sensory,
sympathetic and some parasympathetic neurons in the autonomic
and sensory nervous system [34]. In 1999, a novel human
transcript CG-2 (C9ORF5), was isolated from the familial
dysautonomia candidate region on 9q31 using a combination of
cDNA selection while sequence analysis of CG-2 indicates that it is
likely to encode a transmembrane protein and proposed to be a
candidate for familial dysautonomia [35]. One recent study
reported that miR-32, which maps to intron 14 of C9orf5, is found
at significantly higher levels in prostate cancer tissue when
compared to non-tumor prostate [21]. More recently, SNP
rs523340 within the C9orf5 was reported to be associated with
information processing speed, which is an important cognitive
function that is compromised in psychiatric illness (e.g., schizo-
phrenia, depression) and old age; it shares genetic background
with complex cognition (e.g., working memory, reasoning) [36].
The third signal in the current study, the negative symptoms-
associated genetic variants of the ST3GAL1 gene were also
reported to be risk variants for bipolar disorder (BP) in a number
of previous reports [37–39]. This is compelling because another
ST3-related gene, ST8SIA2, which codes for one of the nerve cell
adhesion molecules, and appears to play a key role in cell-cell
interaction in the developing brain [40] was described as having
an association with SCZ risk [41]. Moreover, according to our
gene ontology analysis, ST3GAL1 contains several closely related
GO categories/KEGG pathways, including O-Glycan biosynthe-
sis and glycosphingolipid biosynthesis in our gene ontology
analysis (Table 3). The latter has also been reported in SCZ
according to one gene expression study, the authors concluded
that the changing pattern of gene expression in glycosphingolipid
biosynthesis could represent an adaptive response to the pathology
of SCZ progression or is a compensatory effect to antipsychotic
medication [42].
Of note, the RNF144 variants showed association not only with
negative symptoms in our current study, but also with metabolic
side effects of antipsychotic drugs [22], therefore, it might be
interesting to examine whether negative symptoms of SCZ
carrying RNF144 variants have different antipsychotic treatment
response as compared with the patients without these variants in
the future.
Another disease-associated gene is CTNNA3, which has been
shown to be associated with other psychiatric disorders, such as
general cognitive ability [43], and Alzheimer’s disease [44,45].
CTNNA3 is a key protein of the adherens junctional complex and
plays a crucial role in cellular adherence [46]. Since this gene is
located within a common fragile site, epigenetically regulated and
transcribed through multiple promoters, it might be interesting to
examine if epigenetic regulation is involved in the pathophysiology
of negative symptoms in the future. Increasing lines of evidence
indicate that the CTNNA3 is also involved in neuronal migration,
synaptogenesis and the formation of neuronal circuits [47]. In
addition, slight migrational disturbances are often seen in the
mesofrontal cortical brain structures of patients with epilepsy [48].
A recent review discussed that deficits in working memory in SCZ
are attributable to specific pathological alterations in the neuronal
circuitry of the dorsolateral prefrontal cortex [49]. In the future,
function analysis and brain structure studies of negative symptoms
of SCZ may provide a deeper understanding of the pathogenesis of
this intermediate phenotype, particularly in patients who carry risk
variants of the CTNNA3.
Two additional negative symptoms-associated SNPs (rs2060531
and rs9869330) at chromosome 3p24.3 were located in the
ZNF385D gene, which also showed an association with BP in a
previous report [50].
The remaining disease-associated genes/loci are less well
understood in psychiatric disorders, like FAM19A1, PLXNA4,
Table 3. Results of Gene Ontology Analysis for Negative Symptoms of SCZ Associated SNPs with PMeta-analysis,3.04610
25, Gene
Ontology Categories with Enrichment P-values ,0.05.
Pathway-ID Pathway Name P-value Genes
path:00603 Glycosphingolipid biosynthesis - globo series 0.0109 ST3GAL1
path:00533 Glycosaminoglycan biosynthesis - keratan sulfate 0.0116 ST3GAL1
path:00604 Glycosphingolipid biosynthesis - ganglio series 0.0116 ST3GAL1
path:00512 O-Glycan biosynthesis 0.0232 ST3GAL1
path:05213 Endometrial cancer 0.0398 CTNNA3
doi:10.1371/journal.pone.0051674.t003
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LOC643308, RNU3P2, PALM2, SCARA5, RPS27AP4, and
NPM1P3. The NAP1L1 and USP22 variants, for example, are
cancer-related genes/loci and the gene, ALCAM (also called
CD166) was originally identified as a transmembrane receptor that
is involved in T-cell activation, development, inflammation and
transendothelial migration of neutrophils, and a cancer susceptible
gene [51]. Therefore, further replication studies are required to
validate if these genes/loci are involved in the development of
negative symptoms of SCZ.
There are a number of strengths in this study. Our sample
size is relatively large for this type of study and is relatively
ethnically homogeneous. The current results of negative
symptoms-associated SNPs together with the results in the in
silico analysis (including gene ontology) provide insight into how
multiple genes might contribute to disease biology of negative
symptoms of SCZ. In addition, by applying more stringent
criteria including the application of permutation analyses, we
ensure that the findings are not due to any sample size
imbalance or by chance. We also realized some limitations in
our study: 1) none of the disease-associated SNPs reached
genome-wide significance level and therefore, the current
findings might be spurious or the results of a type I error
despite the more stringent meta-analysis approach adopted in
our analyses. Future confirmation studies using an independent
sample and/or family-based association studies will provide an
opportunity to more accurately dissect the genetic complexity of
these genetic variants for negative symptoms of SCZ. It is
important to note that a family study design is immune to
population stratification, 2) there is a lack of heritability of
negative symptoms in SCZ, therefore, future studies assessing
the inheritability for this intermediate phenotype will help to
dissect the complex genetics of schizophrenia, and 3) other
variants, such as copy number variation (CNV, recent
discoveries of putatively-causal structural abnormalities) and
rare variants (for example, SNPs less than 1% of minor allele
frequency) may not be captured using common SNPs.
Therefore, future CNV analysis, next generation sequencing
technologies (such as target gene sequencing on these 18 genes/
loci) will provide an opportunity for in-depth molecular profiling
of fundamental biological processes of the negative symptoms-
associated variants in these potential genes/loci identified in the
current study.
Taken together, our findings suggest a possible common genetic
cause of negative symptoms in SCZ, and our current meta-analysis
together with future replication studies in a more homogeneous
and narrowly-defined group of patients will be able to reveal the
genetic basis for negative symptoms of SCZ.
Conclusion
This is the first report identifying common genetic variations
associated with negative symptoms of schizophrenia using meta-
analysis. The current study provides pilot evidence supporting the
use of negative symptoms as an intermediate phenotype to dissect
the complex genetics of schizophrenia. However, additional
studies are warranted to examine the underlying mechanisms of
disease-associated SNPs in these genes/loci.
Materials and Methods
Samples
Two GWAS data sets were used: 1) GAIN sample – 992
European-American (EA) patients with negative symptoms of SCZ
and 1442 EA healthy controls were selected from the publicly
available data from Genome-Wide Association Study of Schizo-
phrenia - Study Accession: phs000021.v2.p1; 2) NonGAIN sample
– 863 EA patients with negative symptoms of SCZ and 1364 EA
controls were selected from Molecular Genetics of Schizophrenia -
nonGAIN Sample (nonGAIN) - Study Accession:
phs000167.v1.p1. NonGAIN sample is part of the Molecular
Genetics of Schizophrenia (MGS) genome wide association study
of 3,972 cases and 3,629 controls after quality control. Unrelated
adult cases with DSM-IIIR (SGI study) or DSM-IV (MGS1,
MGS2 studies) schizophrenia (SCZ) or schizoaffective disorder
(SA) were collected under institutional review board-approved
protocols in three studies, Schizophrenia Genetics Initiative (SGI),
Molecular Genetics of Schizophrenia Part 1 (MGS1), and
MGS23, as previously described in detail in [20] and
phs000167.v1.p1.
Cases selected met criteria for SCZ or schizoaffective disorder
per the Diagnostic and Statistical Manual of Mental Disorders
version IV (DSM-IV). Negative symptoms of SCZ were defined as
a binary trait (present or absent) for SCZ cases per DSM-IV.
Schedule for Assessment of Negative Symptoms (SANS) was used
as the clinical tool for the negative symptoms of SCZ as described
in phs000167.v1.p1. Negative symptoms were defined as deficits of
normal emotional responses or of other thought processes, and
respond less well to medication. Negative symptoms commonly
include flat or blunted affect and emotion, poverty of speech
(alogia), inability to experience pleasure (anhedonia), lack of desire
to form relationships (asociality), and lack of motivation (avolition).
Research suggests that negative symptoms contribute more to poor
quality of life, functional disability, and the burden on others than
do positive symptoms [52].
Genotyping data using the Affymetrix Genome-wide human
SNP Array 6.0 (total 729,454 SNPs) were available for both
datasets.
Statistical Methods
For the initial GWA analysis, HelixTree Software (http://www.
goldenhelix.com/SNP_Variation/HelixTree/index.html, Golden
Helix, Bozeman, MT) was used to assess control genotype data for
conformity with Hardy-Weinberg equilibrium (HWE). To deal
with population stratification, the principal-component analysis
approach with ten principal components (Price et al., 2006) in
HelixTree was used to identify outlier individuals. Then, logistic
regression analysis of negative symptoms of SCZ as a binary trait,
adjusted for age and sex, was performed for GAIN and nonGAIN
samples using PLINK v1.07 [53]. The asymptotic p-value for this
test was observed while the odds ratio with standard error was
estimated. For logistic regression analyses, the additive model was
applied. For statistical significance, we used a very conservative per
test significance level of a= 561028 (Wellcome Trust Case
Control Consortium) [16]. We also used a less stringent criterion
of ‘‘suggestive association’’ with a cut-off of a= 1025. In addition
to obtaining nominal p-values, empirical p-values were generated
by 100,000 permutation tests using Max (T) permutation
procedure implemented in PLINK. This procedure allows
calculation of two sets of empirical significance values: pointwise
estimates of an individual SNP’s significance (empirical pointwise
p-values) and corrected values for multiple testing (corrected
empirical p-values). Results from the two GWA analyses were
directly meta-analyzed by combining the separate results of GAIN
and nonGAIN samples (odds ratio and standard error of odds
ratio) into one meta-analysis of overall effects. For meta-analysis of
two datasets, the basic meta-analysis function in PLINK was
applied. Fixed-effect meta-analysis p-value and fixed-effect OR
were estimated.
Association with Schizophrenia-Negative Symptoms
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Statistical Power Analysis
With the combined sample size of both GWA studies, we
calculated 97.1% of statistical power for negative symptoms of
SCZ (N = 1774) and healthy controls (N = 2726) to detect an
association of p = 561027 based on the GWA significant threshold
using Genetics Power Calculator [54] for a gene of moderate effect
(OR = 1.75); however, the GWA significant threshold is too
conservative since many SNPs are in strong linkage disequilibri-
um.
Bioinformatics Analysis
We also examined whether these negative symptoms of SCZ-
associated variants have an impact on gene function, including
association with microRNA binding sites, being located at species-
conserved regions and having functional importance in gene
regulations using silico analysis: SNP Functional Portal (http://
brainarray.mbni.med.umich.edu/Brainarray/Database/
SearchSNP/snpfunc.aspx), SNP Function Prediction from NIEHS
(http://snpinfo.niehs.nih.gov/snpfunc.htm) and miRdSNP
(http://mirdsnp.ccr.buffalo.edu/search.php). The species-con-
served regions for the SNPs were defined using the UCSC
Genome browser (http://genome.ucsc.edu/, NCBI36/hg18).
Gene ontology analysis was also performed using the ALIGA-
TOR method (Holmans et al., 2009) to investigate whether there
was an enrichment for SNPs in genes in any gene ontology
categories among the SNPs with low, but not genome-wide
significant, p-values. We investigated these SNP sets using a
threshold of P,361025. The SNPs located within and/or close to
genes/loci were included (based on NCBI SNP build 129 and
NCBI sequence build 36.3). One SNP per gene, with the lowest p-
value, was included in the ALIGATOR analysis using 20 000
simulated replicate gene lists and 5000 simulated replicate studies.
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